
- 要聞
- SWS透析護理有限公司(SHSE:688410)備受投資者青睞
SWS Hemodialysis Care Co., Ltd.'s (SHSE:688410) Popularity With Investors Is Clear
SWS Hemodialysis Care Co., Ltd.'s (SHSE:688410) Popularity With Investors Is Clear
With a price-to-earnings (or "P/E") ratio of 52.4x SWS Hemodialysis Care Co., Ltd. (SHSE:688410) may be sending bearish signals at the moment, given that almost half of all companies in China have P/E ratios under 35x and even P/E's lower than 20x are not unusual. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's as high as it is.
Recent times haven't been advantageous for SWS Hemodialysis Care as its earnings have been falling quicker than most other companies. It might be that many expect the dismal earnings performance to recover substantially, which has kept the P/E from collapsing. If not, then existing shareholders may be very nervous about the viability of the share price.

How Is SWS Hemodialysis Care's Growth Trending?
There's an inherent assumption that a company should outperform the market for P/E ratios like SWS Hemodialysis Care's to be considered reasonable.
Taking a look back first, the company's earnings per share growth last year wasn't something to get excited about as it posted a disappointing decline of 64%. Still, the latest three year period has seen an excellent 190% overall rise in EPS, in spite of its unsatisfying short-term performance. Although it's been a bumpy ride, it's still fair to say the earnings growth recently has been more than adequate for the company.
Turning to the outlook, the next year should generate growth of 194% as estimated by the only analyst watching the company. That's shaping up to be materially higher than the 41% growth forecast for the broader market.
With this information, we can see why SWS Hemodialysis Care is trading at such a high P/E compared to the market. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.
The Final Word
We'd say the price-to-earnings ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.
We've established that SWS Hemodialysis Care maintains its high P/E on the strength of its forecast growth being higher than the wider market, as expected. Right now shareholders are comfortable with the P/E as they are quite confident future earnings aren't under threat. It's hard to see the share price falling strongly in the near future under these circumstances.
It is also worth noting that we have found 3 warning signs for SWS Hemodialysis Care that you need to take into consideration.
If you're unsure about the strength of SWS Hemodialysis Care's business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
中國透析護理有限公司(SHSE:688410)的市盈率爲52.4倍,目前可能正在發出消極信號,因爲中國近一半的公司市盈率低於35倍,甚至低於20倍的市盈率並不罕見。 儘管如此,僅僅根據市盈率情況判斷可能不明智,因爲導致市盈率高的原因可能會有解釋。
近期對於中國透析護理來說並不如意,其盈利下降速度比大多數其他公司要快。許多人可能預計糟糕的盈利表現會得到顯著恢復,這導致市盈率沒有崩潰。如果沒有恢復,那麼現有股東可能會非常擔心股價的可持續性。

中國透析護理增長趨勢如何?
存在一種固有的假設,即公司應當表現優於市場,才能認爲像中國透析護理這樣的市盈率是合理的。
首先回顧一下,去年公司的每股收益增長並不令人興奮,因爲它錄得了令人失望的64%下降。儘管短期表現不佳,但最近三年的總體EPS增長率卻達到了出色的190%。雖然曲折,但仍然可以說,最近的盈利增長對公司來說已經足夠了。
轉向展望,根據唯一分析師對公司的估計,明年預計將實現194%的增長。這個增長預期明顯高於更廣泛市場的41%增長預測。
根據這一信息,我們可以看到,SWS透析護理的股價相比市場較高PE,原因在於股東們似乎不急於拋售,因爲這家公司有可能迎來更爲繁榮的未來。
最終結論
我們會說市盈率的力量不是作爲估值工具,而是用於衡量當前投資者的情緒和未來預期。
我們已經確定,SWS透析護理保持了較高的PE,因爲其預期增長高於更廣泛市場,這是意料之中的。目前股東對PE感到滿意,因爲他們相當有信心未來的盈利不會受到威脅。在這些情況下,很難看到股價在不久的將來大幅下跌。
值得注意的是,我們發現了3個SWS透析保健的警告信號,您需要考慮。
如果您對SWS透析保健的業務實力感到不確定,爲什麼不探索一下我們的交互式股票清單,其中包括一些您可能錯過的其他公司的基本經營實質呢?
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Moomoo Securities Australia Limited提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Moomoo Securities Australia Limited, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Moomoo Securities Australia Limited提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Moomoo Securities Australia Limited, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧
